PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $96,556 | +1313.7% | 9,311 | +1852.0% | 0.00% | – |
| Q2 2023 | $6,830 | +56816.7% | 477 | -72.0% | 0.00% | – |
| Q1 2023 | $12 | +140.0% | 1,705 | +250.8% | 0.00% | – |
| Q4 2022 | $5 | -100.0% | 486 | -89.1% | 0.00% | -100.0% |
| Q3 2022 | $49,000 | +8.9% | 4,451 | -17.3% | 0.00% | 0.0% |
| Q2 2022 | $45,000 | -11.8% | 5,380 | +45.6% | 0.00% | – |
| Q1 2022 | $51,000 | +537.5% | 3,696 | +788.5% | 0.00% | – |
| Q4 2021 | $8,000 | -57.9% | 416 | -31.4% | 0.00% | – |
| Q3 2021 | $19,000 | -85.4% | 606 | -84.2% | 0.00% | -100.0% |
| Q2 2021 | $130,000 | +165.3% | 3,833 | +191.3% | 0.00% | +200.0% |
| Q1 2021 | $49,000 | -31.9% | 1,316 | -39.0% | 0.00% | -50.0% |
| Q4 2020 | $72,000 | -82.5% | 2,157 | -80.8% | 0.00% | -60.0% |
| Q3 2020 | $411,000 | +478.9% | 11,212 | +420.5% | 0.01% | +66.7% |
| Q2 2020 | $71,000 | – | 2,154 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,484,274 | $27,873,554 | 11.71% |
| Frazier Life Sciences Management, L.P. | 8,407,152 | $94,328,245 | 5.86% |
| Abingworth LLP | 1,435,106 | $16,101,889 | 5.25% |
| Opaleye Management Inc. | 417,500 | $4,684,350 | 1.63% |
| 683 Capital Management, LLC | 1,350,000 | $15,147,000 | 1.28% |
| Newtyn Management, LLC | 484,074 | $5,431,310 | 1.12% |
| Penn Mutual Asset Management | 62,802 | $704,638 | 0.79% |
| StepStone Group LP | 422,085 | $4,735,794 | 0.62% |
| MPM BioImpact LLC | 195,942 | $2,198,469 | 0.57% |
| Avidity Partners Management LP | 1,900,000 | $21,318,000 | 0.46% |